Cargando…
Microbiota and Phage Therapy: Future Challenges in Medicine
An imbalance of bacterial quantity and quality of gut microbiota has been linked to several pathologies. New strategies of microbiota manipulation have been developed such as fecal microbiota transplantation (FMT); the use of pre/probiotics; an appropriate diet; and phage therapy. The presence of ba...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6313512/ https://www.ncbi.nlm.nih.gov/pubmed/30301167 http://dx.doi.org/10.3390/medsci6040086 |
_version_ | 1783383949764984832 |
---|---|
author | Paule, Armelle Frezza, Domenico Edeas, Marvin |
author_facet | Paule, Armelle Frezza, Domenico Edeas, Marvin |
author_sort | Paule, Armelle |
collection | PubMed |
description | An imbalance of bacterial quantity and quality of gut microbiota has been linked to several pathologies. New strategies of microbiota manipulation have been developed such as fecal microbiota transplantation (FMT); the use of pre/probiotics; an appropriate diet; and phage therapy. The presence of bacteriophages has been largely underestimated and their presence is a relevant component for the microbiome equilibrium. As a promising treatment, phage therapy has been extensively used in Eastern Europe to reduce pathogenic bacteria and has arisen as a new method to modulate microbiota diversity. Phages have been selected and “trained” to infect a wide spectrum of bacteria or tailored to infect specific antibiotic resistant bacteria present in patients. The new development of genetically modified phages may be an efficient tool to treat the gut microbiota dysbiosis associated with different pathologies and increased production of bacterial metabolites and subsequently decrease systemic low-grade chronic inflammation associated with chronic diseases. Microbiota quality and mitochondria dynamics can be remodulated and manipulated by phages to restore the equilibrium and homeostasis of the system. Our aim is to highlight the great interest for phages not only to eliminate and control pathogenic bacterial infection but also in the near future to modulate the microbiota by adding new functions to selected bacteria species and rebalance the dynamic among phages and bacteria. The challenge for the medicine of tomorrow is to re-think and redesign strategies differently and far from our traditional thinking. |
format | Online Article Text |
id | pubmed-6313512 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-63135122019-01-04 Microbiota and Phage Therapy: Future Challenges in Medicine Paule, Armelle Frezza, Domenico Edeas, Marvin Med Sci (Basel) Review An imbalance of bacterial quantity and quality of gut microbiota has been linked to several pathologies. New strategies of microbiota manipulation have been developed such as fecal microbiota transplantation (FMT); the use of pre/probiotics; an appropriate diet; and phage therapy. The presence of bacteriophages has been largely underestimated and their presence is a relevant component for the microbiome equilibrium. As a promising treatment, phage therapy has been extensively used in Eastern Europe to reduce pathogenic bacteria and has arisen as a new method to modulate microbiota diversity. Phages have been selected and “trained” to infect a wide spectrum of bacteria or tailored to infect specific antibiotic resistant bacteria present in patients. The new development of genetically modified phages may be an efficient tool to treat the gut microbiota dysbiosis associated with different pathologies and increased production of bacterial metabolites and subsequently decrease systemic low-grade chronic inflammation associated with chronic diseases. Microbiota quality and mitochondria dynamics can be remodulated and manipulated by phages to restore the equilibrium and homeostasis of the system. Our aim is to highlight the great interest for phages not only to eliminate and control pathogenic bacterial infection but also in the near future to modulate the microbiota by adding new functions to selected bacteria species and rebalance the dynamic among phages and bacteria. The challenge for the medicine of tomorrow is to re-think and redesign strategies differently and far from our traditional thinking. MDPI 2018-10-05 /pmc/articles/PMC6313512/ /pubmed/30301167 http://dx.doi.org/10.3390/medsci6040086 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Paule, Armelle Frezza, Domenico Edeas, Marvin Microbiota and Phage Therapy: Future Challenges in Medicine |
title | Microbiota and Phage Therapy: Future Challenges in Medicine |
title_full | Microbiota and Phage Therapy: Future Challenges in Medicine |
title_fullStr | Microbiota and Phage Therapy: Future Challenges in Medicine |
title_full_unstemmed | Microbiota and Phage Therapy: Future Challenges in Medicine |
title_short | Microbiota and Phage Therapy: Future Challenges in Medicine |
title_sort | microbiota and phage therapy: future challenges in medicine |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6313512/ https://www.ncbi.nlm.nih.gov/pubmed/30301167 http://dx.doi.org/10.3390/medsci6040086 |
work_keys_str_mv | AT paulearmelle microbiotaandphagetherapyfuturechallengesinmedicine AT frezzadomenico microbiotaandphagetherapyfuturechallengesinmedicine AT edeasmarvin microbiotaandphagetherapyfuturechallengesinmedicine |